Study of pancreatic tumors in people with VHL
Part of Brain & nervous system, Cancer, Digestive system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial studies the natural course and management of pancreatic neuroendocrine tumors in people with von Hippel–Lindau (VHL) disease. It may help doctors better predict how these pancreatic findings change over time and how to manage them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with VHL by genetic testing showing a VHL gene change, or by VHL clinical diagnosis.
- You have at least one pancreatic finding seen on a non-invasive scan (like cysts or solid spots that look like certain VHL-related tumor types).
- You are age 12 or older.
- You can understand the study and are willing to sign an informed consent form (and assent if applicable).
- You must be able to do repeated non-invasive imaging over time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how early changes in kidney cells can lead to tumors in people with VHL disease. It may help understand why some people develop kidney cancer and how to prevent it.
This study follows children with Von Hippel-Lindau disease to understand how hemangioblastomas in the brain and spine grow over time. It looks for patterns that might predict future problems, so doctors can plan better care.
This study is for people with von Hippel-Lindau (vHL) disease to collect information for research. It may help researchers better understand the condition and how to care for people with it.
This trial focuses on checking whether a specific inner-ear tumor (called an endolymphatic sac tumor) can be found earlier in people with Von Hippel-Lindau (vHL) disease. It may help doctors detect problems sooner so you can discuss treatment options earlier, if needed.
This study follows people who have von Hippel-Lindau (VHL) over time to better understand how the condition changes. It may help doctors plan future treatments by collecting long-term health information.
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
Hear when a new Von Hippel-Lindau Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.